Leerink reiterates Kalvista stock rating on strong Ekterly sales

KalVista reported Q4 Ekterly (sebetralstat) sales of $35.4M (preannounced ~ $35M), beating Leerink's $24.5M estimate and consensus ~$19–20.7M and driving nearly $50M in sales for the year following the July 2025 approval. The company recorded 1,702 patient start forms through Feb 2026, treated 2,464 attacks in the KONFIDENT‑S OLE, achieved seven regulatory approvals in 2025, and EKTERLY was recommended as a first‑line adolescent therapy in new guidelines. Analysts maintained bullish ratings (Stifel, Needham raised PT to $35; Leerink reiterated Outperform with $22 PT), InvestingPro flags the stock as undervalued vs Fair Value, but KalVista is not yet profitable and is burning cash with a market valuation of $832M (<2x peak sales assumption).

Analysis

The company’s launch dynamics should be evaluated through payer and patient-adoption lenses rather than headline sales alone. Oral, on-demand therapies materially reduce administration friction versus injectables, which shortens the time from prescription to patient use and lowers prior-authorization friction — that mechanism can drive a steeper early adoption curve but also concentrates scrutiny from PBMs looking to control acute spend.

Second-order winners include specialty distributors and CDMOs that can scale oral solid-dose supply quickly; conversely, small-scale manufacturing constraints or single-supplier dependencies would create a bottleneck that caps near-term upside even with strong demand. Clinician and patient preference data that favor convenience will increase stickiness, but true TAM expansion requires label and guideline-driven use beyond early adopters, a 12–24 month path dependent on additional data and regional rollouts.

Key tail risks are classical for early-commercial biotech: access/headroom risk from aggressive PBM contracting, a financing overhang if burn continues before cash-flow breakeven, and any negative safety or real-world effectiveness signals that reverse adoption momentum. Near-term catalysts that matter to valuation are subsequent quarterly demand trajectory, margin progression (gross and SG&A leverage), and material access wins/losses at national payers — these are the gating events that will either justify a multiple expansion or force a reset.

Key Decisions for Investors

• Long KALV (equity): Initiate a starter position ~0.5–1.0% NAV with a 6–12 month horizon. Add on consecutive quarters of sequential revenue and improving gross margin; set a tactical stop at -40% from entry to protect against dilution or access shocks. Target asymmetric upside of ~+100% if continued uptake and improved access push valuation toward mid-cap biotech peers.
• Call spread (options): Buy a 9–12 month KALV LEAP call and finance with a nearer-term call sale (bull-call spread) to lower carry. This expresses multi-quarter commercialization upside while capping premium risk; unwind on a major national formulary win or after any financing announcement.
• Pair trade (relative): Long KALV / short a larger incumbent HAE prophylactic name (size the short at 50–75% of the long) for a 6–12 month trade expressing share-shift to a convenient on-demand option. Rationale: capture differential adoption if on-demand displaces some episodic use of more expensive injectables; convert to pure long if company prints durable growth and access improves.
• Event hedge: If you hold KALV into next quarter print, buy a protective put with 3–6 month tenor sized to limit downside to ~30–35% of position value. Conversely, if a financing is announced, take 50–75% profits and reassess post-dilution to avoid value erosion from equity issuance.